CD274 and non-small cell lung carcinoma: The introduction of immune checkpoint inhibitors targeting the programmed-death 1/programmed-death ligand 1 (PD-1/PD-L1) and/or cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) pathways has improved the treatment of advanced NSCLC in recent years, with several RCTs demonstrating survival advantage against or in combination with chemotherapy, in first and subsequent lines of therapy [102,103,104,105,106,107,108,109,110].